Aprea Therapeutics, Inc. (APRE) Key Statistics & Financial Ratios

Aprea Therapeutics, Inc. (APRE) — Price $0.73 — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for Aprea Therapeutics, Inc. (APRE). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors.

Stock Data

Price$0.73
Market Cap$9M
Enterprise Value-$32.2M
Beta1.57
ExchangeNASDAQ
CountryUS

Valuation Multiples

P/E Ratio-0.57
Price / Book1.03
P/S0.00
EV/EBITDA2.62
EV/Sales0.00
EV/FCF2.64
P/FCF-0.75
Earnings Yield-31.50%
FCF Yield-134.69%
Dividend Yield0.00%

Profitability

Gross Margin0.00%
EBIT Margin0.00%
EBITDA Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Return on Equity-46.72%
Return on Assets-29.10%
Return on Invested Capital-33.73%
Return on Capital Employed-33.73%

Financial Health

Current Ratio13.55
Quick Ratio13.55
Cash Ratio13.33
Debt / Equity0.00
Debt / Assets0.00%
Net Debt / EBITDA3.36
Interest Coverage0.00

Per-Share Data

Revenue per share0.00
Book Value per share0.72
Cash per share0.77
FCF per share-0.23
Tangible Book Value per share0.72
Dividend per share0.00

Related companies: ACXP · ADIL · APVO · BCDA · CELZ · GLTO · HCWB

Explore sector: Healthcare · Biotechnology

More sections of APRE: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks